Skip to main content

Aditxt Inc. (NASDAQ: ADTX) Planning Nationwide Rollout of its AditxtScore(TM) Immune Monitoring Platform

  • Aditxt recently entered a multi-year partnership with GRS for the promotion of its proprietary AditxtScore Immune Monitoring Platform
  • Aditxt plans to roll out the monitoring platform to medical offices, pharmacies, laboratories, and employers across the country, with promotion through nationwide television commercials 
  • AditxtScore(TM) monitors the current immune response not genetic sequencing 

Continuing research into COVID-19 is being done worldwide, with some researchers showing concern among the population of vaccinated individuals testing positive for the virus – including concerns about the durability of protection against highly contagious emerging strands. Researchers are still learning more about vaccinations against viruses and diseases in comparison to the body’s natural immune responses (https://ibn.fm/m2630).

“Following our comprehensive profiling of the effects of neutralizing antibodies, T cell immunity and non-neutralizing alternate antibody msabe found correlates of immunity in the context of both complete protection and mitigation of viral burden in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.